M&A is a relevant mega trend in the life sciences industry, ~$200B of deals are getting closed per year. Companies
need to proactively manage key challenges during this integration, specifically related to significant delays in
completing integration per original plans, disruption in supply, lack of active management of third party distributor
contracts, and licenses and compliance issues. Companies need to address M&A from a cross-functional approach
across regulatory-quality-supply, specifically, they need to assess scope of impact holistically, setup cross-functional
governance at global-regional levels, develop integrated submission strategies, and execute and track submission
plans in coordination with global-regional governance forums.